3,956 Eli Lilly and Company $LLY Shares Sold by Brookstone Capital Management

Key Points

• Brookstone Capital Management reduced its Eli Lilly stake by 6%, selling 3,956 shares and retaining 61,439 shares valued at approximately $71.1 million.
• Institutional investors own 82.53% of Eli Lilly, while company insiders have sold 13,500 shares worth about $16.0 million over the past 90 days, primarily under pre-arranged trading plans.
• Eli Lilly reported strong quarterly results, with EPS of $8.38 and revenue of $22.97 billion, beating estimates; analysts maintain a “Moderate Buy” consensus and an average price target of $1,317.93.

Brookstone Capital Management trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,439 shares of the company's stock after selling 3,956 shares during the period. Eli Lilly and Company accounts for approximately 0.7% of Brookstone Capital Management's investment portfolio, making the stock its 26th biggest position. Brookstone Capital Management's holdings in Eli Lilly and Company were worth $71,090,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Coastal Bridge Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $2,959,000. Mosaic Family Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 70.6% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock valued at $4,144,000 after purchasing an additional 1,430 shares during the last quarter. Moran Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 85.6% during the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company's stock worth $25,072,000 after buying an additional 9,638 shares in the last quarter. Generali Investments Management Co LLC raised its holdings in shares of Eli Lilly and Company by 17.5% during the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company's stock worth $12,258,000 after buying an additional 1,521 shares in the last quarter. Finally, Amundi raised its holdings in shares of Eli Lilly and Company by 9.9% during the 1st quarter. Amundi now owns 5,055,025 shares of the company's stock worth $4,649,464,000 after buying an additional 454,549 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Activity

In other news, CAO Donald Zakrowski sold 2,000 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Price Performance

LLY stock opened at $1,275.50 on Friday. The firm has a market cap of $1.20 trillion, a price-to-earnings ratio of 42.80, a PEG ratio of 1.70 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 12-month low of $809.63 and a 12-month high of $1,321.21. The company's fifty day simple moving average is $1,186.64 and its 200 day simple moving average is $1,120.24.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business's quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts expect that Eli Lilly and Company will post 33.22 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on LLY shares. Bank of America lifted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a report on Friday, July 10th. Citigroup boosted their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Guggenheim lifted their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a research report on Friday, September 18th. TD Cowen restated a "buy" rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,317.93.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Manufacturing expansion supports long-term growth. Lilly broke ground on a $5 billion facility in Goochland County, Virginia, its first U.S. site designed to produce both active pharmaceutical ingredients and finished medicines. The project is part of a more than $50 billion U.S. manufacturing expansion and is expected to create 650 jobs, improving supply capacity for next-generation cancer and other complex medicines. Lilly Richmond manufacturing facility announcement
• Positive Sentiment: Weight-loss drug demand remains a major growth driver. Analysts expect emerging-market sales of weight-loss drugs to become a significant opportunity, supporting the long-term outlook for Mounjaro, Zepbound and related incretin products. Lilly’s recent growth has been driven by increasing volume, even as pricing has declined. JP Morgan emerging-market weight-loss drug outlook
• Positive Sentiment: Some analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast for Lilly to $47.77 from $47.30, signaling confidence in the company’s longer-term earnings trajectory. Erste Group Bank EPS estimate update
• Neutral Sentiment: ESG progress may support the company’s reputation but is unlikely to drive near-term trading. Lilly was cited for combining philanthropy with environmental initiatives while maintaining rapid commercial growth. Eli Lilly sustainability leadership article
• Negative Sentiment: Near-term earnings risk is weighing on sentiment. Previews anticipate a decline in third-quarter earnings, raising concerns that the stock’s elevated valuation leaves limited room for disappointment ahead of the upcoming report. Lilly Q3 earnings preview
• Negative Sentiment: Institutional trimming adds selling pressure. Polen Capital reduced its position in Lilly during the third quarter, although it reportedly maintained confidence in the company’s outlook. Polen Capital trims Lilly position

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.